Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Axsome Therapeutics ( (AXSM) ) has provided an announcement.
On January 12, 2026, Axsome Therapeutics reported preliminary, unaudited net product revenue of approximately $196.0 million for the fourth quarter of 2025 and $638.5 million for full-year 2025, reflecting robust year-over-year growth of 65% and 66%, respectively, compared with 2024. The gains were driven primarily by AUVELITY, which generated an estimated $155.1 million in fourth-quarter sales and $507.1 million for the year, while SUNOSI contributed about $36.7 million for the quarter and $124.8 million for the year, and newly launched SYMBRAVO, introduced commercially in June 2025, added $4.1 million in fourth-quarter sales and $6.6 million for the year. These figures underscore Axsome’s accelerating commercial momentum in CNS therapies and highlight AUVELITY’s role as the company’s key revenue engine, while the early contribution from SYMBRAVO suggests expanding product breadth, although final results remain subject to completion of standard financial closing procedures and could differ from the preliminary estimates.
The most recent analyst rating on (AXSM) stock is a Buy with a $217.00 price target. To see the full list of analyst forecasts on Axsome Therapeutics stock, see the AXSM Stock Forecast page.
Spark’s Take on AXSM Stock
According to Spark, TipRanks’ AI Analyst, AXSM is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, negative cash flow, and high leverage). Offsetting this are constructive technical trends and a strong earnings-call backdrop with rapid revenue growth and pipeline/regulatory progress, though valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on AXSM stock, click here.
More about Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company focused on central nervous system (CNS) conditions, developing differentiated therapies with novel mechanisms of action to address major unmet needs in neuroscience. Its portfolio includes FDA‑approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple late-stage development programs targeting serious neurological and psychiatric disorders affecting over 150 million people in the United States.
Average Trading Volume: 601,480
Technical Sentiment Signal: Buy
Current Market Cap: $8.45B
Find detailed analytics on AXSM stock on TipRanks’ Stock Analysis page.